Shots:

• The companies will co-fund the clinical trial which is expected to include three P-III trials for advanced non-small cell lung cancer (NSCLC)- castration-resistant prostate cancer (CRPC) and renal cell carcinoma (RCC)
• The focus of the collaboration is to evaluate Exelixis’ Cabometyx (cabozantinib) with Roche’s Tecentriq (atezolizumab) in patients with locally advanced or metastatic solid tumors. The collaboration is based on P-Ib COSMIC-021 trial which is enrolling 24 expansion cohorts in 12 n 12 tumor types including RCC- NSCLC- and CRPC
• Cabometyx is an inhibitor of receptor tyrosine kinases approved in the US for the treatment of patients with advanced RCC and for the treatment of patients with hepatocellular carcinoma who have been previously treated with sorafenib and in Eu also

Click here to read full press release/ article

Ref: Exelixis | Image: Roche